Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

The gene therapy market is characterized by a healthy drug pipeline, with 10 approved<RootsAnalysis>


Narender

3 views

Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.

 

To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

The USD 14.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

§  Therapeutic approach

§  Gene augmentation

§  Oncolytic therapy

§  Immunotherapy

§  Others

 

§  Type of gene therapy

§  Ex vivo

§  In vivo

 

§  Type of vector used

§  Adeno associated virus

§  Adenovirus

§  Herpes simplex virus

§  Lentivirus

§  Plasmid DNA

§  Retrovirus

§  Others

 

§  Key therapeutic areas

§  Autoimmune disorders

§  Cardiovascular diseases

§  Dermatological disorders

§  Genetic disorders

§  Hematological disorders

§  Metabolic disorders

§  Muscle-related diseases

§  Oncological disorders

§  Ophthalmic diseases

§  Others

 

§  Route of administration

§  Intraarticular

§  Intracerebellar

§  Intradermal

§  Intramuscular

§  Intratumoral

§  Intravenous

§  Intravesical

§  Intravitreal

§  Subretinal

§  Others

 

§  Key geographical regions

§  North America

§  Europe

  • Asia-Pacific 

 

The Gene Therapy Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

§  Abeona Therapeutics

§  Advantagene

§  Biogen

§  bluebird bio

§  Castle Creek Biosciences

§  CG Oncology

§  FerGene

§  Freeline Therapeutics

§  Gradalis

§  Helixmith

§  Inovio Pharmaceuticals

§  Kolon TissueGene

§  Krystal Biotech

§  Lysogene

§  Neurophth Therapeutics

§  OncoSec Immunotherapies

§  Orchard Therapeutics

§  Pfizer

§  Sangamo Therapeutics

§  Spark Therapeutics

§  uniQure Biopharma

§  VBL Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

4. Gene Delivery Vectors
 

5. Regulatory Landscape and Reimbursement Scenario
 

6. Market Overview
 

7. Competitive Landscape 
 

8. Marketed Gene Therapies
 

9. Key Commercialization Strategies
 

10. Late Stage (Phase II/III and Above) Gene Therapies
 

11. Emerging Technologies
 

12. Key Therapeutics Areas
 

13. Patent Analysis
 

14. Mergers and Acquisitions

 

15. Funding and Investment Analysis

 

16. Clinical Trial Analysis

 

17. Cost Price Analysis

 

18. Big Pharma Players: Analysis of Gene Therapy Related Initiatives

 

19. Demand Analysis

 

20. Market Forecast and Opportunity Analysis

 

21. Vector Manufacturing

 

22. Case Study: Gene Therapy Supply Chain

 

23. Conclusion

 

24. Interview Transcripts

 

25. Appendix 1: Tabulated Data

 

26. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...